Drug intelligence / Profile preview

QLM3003

Development stage: Phase 3
Lead developer: Qilu Pharmaceutical
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

QLM3003 is a topical ointment under development by Qilu Pharmaceutical for the treatment of atopic dermatitis. It is currently in phase 3 clinical trials, where it is being evaluated for efficacy and safety in patients with mild to moderate atopic dermatitis. The drug is administered topically and has been studied in multicenter, randomized, double-blind, placebo-controlled trials. The precise mechanism of action has not been disclosed publicly[1][3][7]. Its development focuses on immune system diseases, specifically targeting atopic dermatitis.

Beyond the preview

Go deeper on QLM3003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLM3003.

Explore the full profile